15.94

1.67% -0.2324

Arcturus Therapeutics Holdings Inc (ARCT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arcturus Therapeutics Holdings Inc stock is traded at $15.94, with a volume of 89,105. It is down -1.67% in the last 24 hours and down -23.85% over the past month. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Previous Close:

$16.17

Open:

$16.22

24h Volume:

89,105

Relative Volume:

0.24

Market Cap:

$452.36M

Revenue:

$157.75M

Net Income/Loss:

$-29.73M

P/E Ratio:

5.3303

EPS:

2.99

Net Cash Flow:

$-21.00M

1W Performance:

-13.30%

1M Performance:

-23.85%

6M Performance:

-46.73%

1Y Performance:

-30.69%

1-Day Range:

$15.50

$16.25

1-Week Range:

$14.93

$18.09

52-Week Range:

$14.93

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name

Arcturus Therapeutics Holdings Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(858) 900-2660

Address

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Employee

180

Twitter

@ArcturusRx

Next Earnings Date

2024-11-07

Latest SEC Filings

ARCT's Discussions on Twitter

Compare ARCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARCT	15.91	452.36M	157.75M	-29.73M	-21.00M	2.99
VRTX	446.50	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	739.88	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.80	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.97	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.80	24.49B	3.30B	-501.07M	1.03B	11.54

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-24-23	Initiated	William Blair	Outperform
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-14-22	Resumed	Wells Fargo	Overweight
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform
Nov-03-22	Upgrade	Citigroup	Neutral → Buy
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral
Apr-21-22	Downgrade	Citigroup	Buy → Neutral
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight
Jun-25-21	Resumed	Goldman	Neutral
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell
Jan-19-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-15-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-07-21	Initiated	Wells Fargo	Overweight
Dec-29-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-29-20	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-29-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-23-20	Downgrade	ROTH Capital	Buy → Sell
Dec-08-20	Reiterated	B. Riley Securities	Buy
Dec-07-20	Reiterated	B. Riley Securities	Buy
Oct-26-20	Initiated	Barclays	Overweight
Oct-06-20	Initiated	Citigroup	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-30-20	Resumed	ROTH Capital	Buy
Jul-16-20	Initiated	Raymond James	Outperform
Jul-13-20	Initiated	B. Riley FBR	Buy
Jun-09-20	Downgrade	WBB Securities	Buy → Hold
Feb-11-20	Initiated	Robert W. Baird	Outperform
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Apr-05-19	Initiated	H.C. Wainwright	Buy
Sep-20-18	Upgrade	WBB Securities	Buy → Strong Buy
Jan-22-18	Initiated	Chardan Capital Markets	Buy

View All

Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News

Nov 18, 2024

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance

Nov 18, 2024

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | ARCT Stock News - StockTitan

Nov 18, 2024

Nov 16, 2024

Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it

Nov 15, 2024

Nov 14, 2024

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha

Nov 14, 2024

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online

Nov 12, 2024

Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St

Nov 12, 2024

Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations

Nov 12, 2024

Nov 11, 2024

Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA | ARCT Stock News - StockTitan

Nov 11, 2024

What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat

Nov 11, 2024

Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Business Wire

Nov 11, 2024

Nov 09, 2024

Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia

Nov 09, 2024

Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com

Nov 08, 2024

Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 08, 2024

ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Nov 08, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World

Nov 08, 2024